Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8442624 | European Journal of Cancer | 2015 | 6 Pages |
Abstract
Thus, the PD-1/PD-L1 pathway seems activated in a fraction of small cell carcinomas. The carcinoma cells were negative in all cases, PD-L1 was expressed in tumour-infiltrating macrophages and was correlated with tumour-infiltrating lymphocytes. Patients with stromal PD-L1/PD-L2 expression may respond to anti-PD-1 treatment. Thus, evaluation of the composition of the tumour microenvironment should be included in clinical trials. Besides conventional immunohistochemistry, RNA-seq seems suitable for detection of PD-L1/PD-L2 expression and might prove to be more sensitive.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anne M. Schultheis, Andreas H. Scheel, Luka OzretiÄ, Julie George, Roman K. Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner,